<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4002">
  <stage>Registered</stage>
  <submitdate>30/06/2013</submitdate>
  <approvaldate>30/06/2013</approvaldate>
  <nctid>NCT01894724</nctid>
  <trial_identification>
    <studytitle>Targeted Hypothermia During Cardiac Surgery</studytitle>
    <scientifictitle>Targeted Cerebral Hypothermia During Cardiac Surgery: A Feasibility Trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CS-1.0</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cardiac Surgery</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - NeuroSave device

Experimental: NeuroSave Device - Targeted Hypothermia with NeuroSave Device


Treatment: devices: NeuroSave device


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Freedom from major adverse events related to the use of the NeuroSave device</outcome>
      <timepoint>Surgery through discharge (up to 5 days post-surgery)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Brain-core temperature differential during cardiac surgery</outcome>
      <timepoint>Continuously assessed over course of cardiac surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  =18 years of age

          -  Undergoing coronary revascularization or valvular cardiac surgery

          -  The study patient or the study patient's legal representative has been informed of the
             nature of the study, agrees to its provisions and has provided written informed
             consent as approved by the Human Research Ethics Committee (HREC) of the respective
             clinical site

          -  The study patient agrees to comply with all study -related procedures</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Women known or suspected to be pregnant (as confirmed by a pregnancy test for all
             women of child-bearing age)

          -  Past history of cerebrovascular accident (stroke or TIA)

          -  History of clinically diagnosed active psychiatric conditions

          -  Emergency or salvage cardiac valve operations

          -  Body weight &lt; 50 kg

          -  Leukopaenia (WBC &lt; 3000 cell/mL), anaemia (Hgb &lt; 11g/dL), Thrombocytopaenia (Plt &lt;
             50,000 cell/mL)

          -  Active upper GI bleeding within 3 months (90 days) prior to procedure

          -  Renal insufficiency (creatinine &gt; 265 micromol/L) and/or renal replacement therapy at
             the time of screening

          -  Estimated life expectancy &lt; 12 months (365 days)

          -  Structural abnormality or disease of nose, mouth, pharynx and oesophagus (excluding
             gastric reflux oesophagus disease),

          -  Currently participating in an investigational drug or another device study that would
             potentially impact the results of this study as determined by the PI. Note: Trials
             requiring extended follow-up for products that were investigational, but have since
             become commercially available, are not considered investigational trials</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>5</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>NeuroSave Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study designed to evaluate the safety and feasibility of the NeuroSave device to rapidly
      reduce brain temperature while maintaining the brain at a lower temperature than the body
      core during cardiac surgery.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01894724</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Silvanna Marasco</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>